RTTNews | Aug 25, 2021 07:44AM EDT

07:44 Wednesday, August 25, 2021 (RTTNews.com) - FibroGen, Inc. (FGEN) on Wednesday announced positive topline results from the Phase 2 study of roxadustat, dubbed Whitney, in chemotherapy-induced anemia (CIA).

Phase 2 study of roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies has been met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion.

Roxadustat is a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

FibroGen said roxadustat was well tolerated and there were no substantive differences in treatment-emergent adverse events between arms with different starting doses.

Complete results of the study is expected to be presented at a medical meeting later this year.

Read the original article on RTTNews ( https://www.rttnews.com/3220976/fibrogen-reports-positive-topline-results-from-phase-2-study-of-roxadustat.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved